Neuroblastoma is a malignant solid tumor frequently occurring in childhood. This disease has an incidence rate of one case per 8000 children, accounting for ~9% of all cancers in children under the age of 15 [Schwab et al., 2003] . Neuroblastoma arises from neuroectodermal cells derived from the neural crest and takes place in the adrenal medulla or paraspinal symphatetic nervous system [Schwab et al., 2003; Bown, 2001] . In general, infants less than one year old with neuroblastoma present with lower stage and less aggressive disease, which are usually chemosensitive and thus curable [Bown, 2001] . However, in children over one year old, the disease is often much more aggressive, metastatic and chemoresistant, and therefore has a high mortality rate [Bown, 2001] . The biological mechanism underlying this substantial clinical heterogeneity of neuroblastoma is still elusive.
To improve the understanding of neuroblastoma, many genetic and biological features have been investigated [Riley et al., 2004] . A number of studies have also been performed to identify tumor markers for facilitating the screening, diagnosis, prognosis, or monitoring of the disease to improve cure rates [Riley et al., 2004] . However, specific and sensitive diagnostic and prognostic markers have not been found yet. A recent study also revealed that relapse or progression in neuroblastoma cannot be reliably detected by monitoring the current tumor markers alone [Simon et al., 2003 ]. This presents a great need of continued effort to identify useful biomarkers for designing novel diagnostic tools and therapeutic strategies.
As an emerging powerful biological research technique, proteomics has recently become a key tool in the identification of biomarkers and disease targets [He et al., 2003; Zhu et al., 2003; Petricoin et al., 2003 ]. An advantage of proteomics is its ability to simultaneously inspect the whole proteome so that correlated proteins altered in expression and modification corresponding to a disease condition can be identified in a single experiment. This makes it possible to combine several protein markers together to form an index with higher sensitivity and specificity in the detection and monitoring of disease. 2D-gel based proteomics has been extensively used to study disease pathogenesis and to identify novel potential biomarkers for various cancers including neuroblastoma [Campostrini et al., 2004; Wimmer et al., 1996; Shin et al., 2003; Zhou et al., 2003 ]. However, 2D-gel electrophoresis has its limitation in protein separation. For example, proteins that have molecular weights (MW) less than 10 kDa and isoelectric points (pI) less than 3 and higher than 11 cannot be separated or well displayed in gels. As a complementary tool, ProteinChip SELDI-TOF technology is much useful in analyzing proteins with low MWs covering the entire pI range. Other advantages of ProteinChip SELDI-TOF include its high sensitivity and straightforwardness especially in examining body fluids such as serum samples. In this study, serum specimens from neorublastoma patients were analyzed by using five types of protein chips. By comparing the serological protein profiles between patients and healthy controls, a number of proteomic features were found significantly altered. Some of the alterations can be detected in more than one type of protein chips simultaneously. None of these expression differences was found in similar comparisons between normal samples and hepatomas. The interesting results demonstrated that serological biomarker identification by ProteinChip SELDI TOF technology for neuroblastoma is promising.
METHODS AND EXPERIMENTAL PROCEDURES

Patient Materials
With patients' consent, we collected blood samples from neuroblastoma patients at the Queen Mary Hospital, Hong Kong. The study was approved by the research ethics committee of the University of Hong Kong. Since few neuroblastoma cases were available, we only included 5 serum samples from patients admitted in Queen Mary Hospital in last two years. Table 1 lists the patients' information and histology. All neuroblastoma cases were confirmed histologically, with three at stage IV, one at stage III and one at stage II. Bone morrow metastasis was found at all the advance stages of IV and III. Serum samples from 10 healthy subjects were used as normal control. For comparison, another sample group containing 8 normal and 8 hepatoma sera was recruited and subjected to similar screening. All blood samples were distributed into 50µl aliquots and were stored at -80 °C before assay.
ProteinChip Analysis of Serum Samples
Five types of protein chips including IMAC3, WCX2, SAX2, H50 and NP20 from Ciphergen Biosystems (Frement, CA, USA) were used in the protein profiling of the serum samples. These protein chips have different surface affinity properties with IMAC3 for metalbinding proteins, WCX2 (weak cation exchanger) for positive-charge molecules, SAX2 (strong anion exchanger) for negative charge molecules, H50 for hydrophobic peptides and 
SELDI-TOF MS and Data Analysis
Mass spectrometric analysis was performed by SELDI-TOF mass spectrometry in a PBS-II ProteinChip reader (Ciphergen Biosystems) according to an automated data collection protocol. This includes an average of 255 laser shots to each spot with a laser intensity of 240 and 265, respectively, dependent on the measured region (low = 2-20 kDa and high = 20-200 kDa, respectively). The detector was run at a sensitivity of 9. Spectral analysis was carried out using the ProteinChip software version 3.1 (Ciphergen Biosystems). All mass spectra were normalized to have the same total ion current. Cluster analysis of the detected signals and the determination of respective p values were carried out with the Biomarker Wizard Program (Version 3.0; Ciphergen Biosystems). For p value calculation, spectra with at least 10 signals in the range between 2 kDa and 20 kDa exhibiting a signal-to-noise ratio of at least 5 were selected and analyzed with the Mann-Whitney U test for non-parametric data sets.
RESULTS AND DISCUSSION
In order to comprehensively analyze the serological proteins, five types of protein chips, H50, IMAC3, NP20, SAX2 and WCX2, were used for the protein profiling of the serum samples from neuroblastoma patients and healthy subjects. Figure 1 shows representative protein profiles from 1.5 -20 kDa detected by the five protein chips for the tumor and normal sera side by side. While the protein profiles among different chips are largely different, some proteomic signals can be visualized with more than one type of chips.
Within each type of protein chip, significant differences in proteomic features between tumor and normal samples were evident.
When detailed cluster analyses were performed on the polypeptide peaks for each chip, a number of different features with a statistical significance were presented. Since only five cases of serum samples in tumor group were used in this study, we applied highly restricted parameters on selecting significant changes in protein expression. Only those polypeptide bands that varied more than 3 fold in intensity with p values less than 0.05 were regarded as significant alterations. Under this condition, ten protein features showing significantly different in intensity between tumor and normal sera were detected by ProteinChip H50 array, with eight peaks obviously decreasing and the other two substantially increasing in expression in neuroblastoma (Table 2) . Likewise, Table 3 be seen by all five arrays and exhibits consistent decrease in expression in tumor sera. Other peaks that can be detected by more than one chip include those at 4058.65, 4215.34, 6919.62, 8764.86, 9286.89, 13732.84, and 13868 .63 Da, respectively. Table 7 lists all 9 protein features that can be identified by more than one array, in which two display constant increase and the other 7 were constantly depleted in tumor samples.
In a separated testing experiment, the positive control group containing 8 normal and 8 hepatoma serum specimens was also subjected to similar analyses by the 5 protein chip arrays. When cluster comparisons were made between normal and hepatoma samples respectively for each type of chips, many differences were observed in terms of expression intensity (data will be published elsewhere) but none of them resembles the similar trend of alterations with the 9 polypeptide features detected in the neuroblastoma training group. Only one peak at 8762.29 Da, which was detected by SAX2 chip and exhibited 3.1-fold decrease in intensity with a p value of 0.011, is close to but may not be the same to the peak at 8764.86 Da (see above). These results suggest that the proteomic features identified by the protein chips have a high specificity.
TagIdent tool in ExPASy molecular server (http://ca.expasy.org/tools/tagident.html) was used to search for a hint of the protein identities for these 9 polypeptide variants in neuroblastoma. All possible protein IDs in HOMO SAPIENS database are listed in Table 7 and complement C4 precursor (MW: 8764.07 Da). Other possible matches can be found in Table 7 .
Although protein identification through TagIdent is basically preliminary, some proteins, if validated, are really related to tumorigenesis. For example, PYY is a regulatory neuropeptide that plays a significant role in inhibiting cancer cell growth [Tseng et al., 2002] .
An under-expression of PYY has been implicated to the development and progression of colon adenocarcinoma and PYY treatment suppressed growth in pancreatic and breast tumors [Tseng and Liu, 2002] . PYY exerts action through its receptor [Freitag et al., 1995a ].
Neuroblastoma cells have been shown to largely express PYY receptor [Kanatani et al., 1996; Freitag et al., 1995b; Miura et al., 1994] , which may be a response to the less availability of PYY. The substantially decreased level of peptide YY-like precursor observed in current neuroblastoma sera may reflect the suppressed expression of the protein in cells, a relevant aspect in neuroblastoma development. Another low level polypeptide in neuroblastoma sera is platelet factor 4 precursor (PF4). PF4 is a CXC chemokine secreted by activated platelets and expressed during megakaryocytic differentiation. PF4 can inhibit endothelial cell proliferation in vitro and angiogenesis and tumor growth in vivo in experimental animals [Li et al., 2003; Long et al., 1990; Griffioen et al., 1999] . The marked decrease of PF4 level in cancer sera suggests the lacking activity of tumor inhibition of the protein in the patients.
Two commonly and strikingly up-regulated proteins in neuroblastoma sera were identified as polyamine oxidase (PAO) splice variant 3 and glutathione S-transferase isoform 3 (GSTM3). PAO splice variant 3 is an isoform of the PAO enzymes [Murray-Stewart et al., 2002] . PAO takes part in the metabolism of polyamines, the organic cations with multiple functions in cell proliferation and differentiation [Thomas et al., 2003] . The regulation of this PAO enzyme has been implicated to have a role in facilitating apoptosis of cancer cells [Thomas and Thomas, 2003] . GSTM3 is a phenotype of the superfamily of GST enzymes involved in detoxification process. GSTs catalyze the glutathione conjugation reaction with eletrophilic compounds and carcinogens [Tsuchida et al., 1992] . The significant increase of GSTM3 level in neuroblastoma may correspond to the initiation of self protective machinery of cells in tumorigenetic process. The over-expressions of GSTs have been found in various cancers (For example [Lafuente et al., 1998; Li et al., 1997; Zhang et al., 1994] ).
In summary, we have used five types of protein chips to examine the serum specimens from neuroblastoma patients and healthy subjects. Through SELDI-TOF mass spectroscopic analysis, a number of proteins or polypeptides were found to be significantly different in expression levels between the tumor and control sera. Some of these differences can be simultaneously distinguished by more than one type of protein chips, confirming that the alterations are stable and consistently detectable in serum. Possible protein identification revealed clues that these altered proteins may be related to the tumorigenesis of neuroblastoma. In addition, none of these alterations was found in the positive control group containing normal and hepatoma samples, indicating a high specificity for neuroblastoma.
The present results demonstrate that ProteinChip SELDI-TOF technology is sensitive in identifying proteins/polypeptides changed in tumor serum and it is promising to combine these altered protein features as potential biomarkers for clinical application. More serum specimens should be screened to test the sensitivity and specificity of the proteomic features as diagnostic biomarkers. 
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